Viridian Therapeutics Inc. (0K1R)
London Stock Exchange · UK · prices in USD · close of 27 Oct 2026
Key indicators
| Last close | USD 23.84 |
|---|---|
| 52-week range | 13.25 – 34.31 |
| Return, 1 month / 3 months | +15.4% / +20.0% |
| Return, 1 year / 3 years | +4.9% / +86.7% |
| Trend | Uptrend |
| RSI (14) | 68 |
| Volatility (1 year) | 75.4% |
| Worst drawdown (1 year) | -61.1% |
| Average daily value traded | 0.03M USD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Viridian Therapeutics is a clinical-stage biotechnology company based in Waltham, Massachusetts, in the United States. It develops antibody-based medicines for serious autoimmune and inflammatory conditions, with its main work focused on treatments for thyroid eye disease. Its pipeline includes therapies designed to block a receptor involved in the disease process, and the company works with researchers and clinicians to test these candidates in clinical studies. Viridian's activities centre on drug development rather than on selling commercial products.
The shares are listed on the London Stock Exchange in UK under the code 0K1R, and the price on this page is in US dollars (USD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Viridian Therapeutics Inc. (0K1R) trades on the London Stock Exchange in UK. It last closed at USD 23.84 on 27 October 2026.
Its price-based Market X-Ray is 41 out of 100 (a weak price profile), ranking 2,599 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 4.9% and over the last three months it rose 20.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 49 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | 9.4% | ||
| From 52-week high | -30.1% | ||
| Momentum | 73 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 20.0% | ||
| 6-month return | 77.1% | ||
| 12-month return, skipping the last month | -9.2% | ||
| Stability (higher is calmer) | 12 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 75.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -61.1% | ||
| Liquidity | 21 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.03M USD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +7.4% |
|---|---|
| 1 month | +15.4% |
| 3 months | +20.0% |
| 6 months | +77.1% |
| 1 year | +4.9% |
| 3 years | +86.7% |
| 5 years | +34.3% |
Signals
| 50-day / 200-day average | 21.62 / 21.80 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.02 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.